Literature DB >> 22151654

Treatment of failed back surgery syndrome.

A Dario1, G Fortini, D Bertollo, A Bacuzzi, C Grizzetti, S Cuffari.   

Abstract

Objectives. To evaluate the long-term results of different therapies for failed back surgery syndrome (FBSS). Materials and Methods. From 1992 to 1997, 49 patients were treated for FBSS. Twenty patients were treated medically. Twenty-four patients, who did not respond to medical therapy, underwent spinal cord stimulator (SCS) implant and five underwent further spine surgery. All patients were evaluated by VAS, PDI, and the Oswestry Scales before treatment and at follow-up. Leg pain, back pain, work status or daily activities, drug side effects, and use of analgesic medications after implantation were examined. Follow-up ranged from 24 to 84 months (mean 42 months). Results. At last follow-up, the patients treated medically demonstrated good results on leg and low back pain in eight cases; in other cases, good results were transitory and several therapeutic courses were necessary to control the pain. Two patients treated medically had substantial side effects. All but two patients treated with SCS demonstrated good results for their leg pain; whereas those treated for back pain with SCS had poor results. Two patients still needed continuous drug administration. Conclusions. Medical therapy is effective for leg and back pain; nevertheless, several courses of therapy may be necessary. SCS is an effective treatment for leg pain, however, its effectiveness on back pain appears to be inadequate.

Entities:  

Year:  2001        PMID: 22151654     DOI: 10.1046/j.1525-1403.2001.00105.x

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  9 in total

Review 1.  [SCS as a treatment option for failed back surgery syndrome].

Authors:  V Tronnier
Journal:  Orthopade       Date:  2016-09       Impact factor: 1.087

2.  Increasing Rates of Imaging in Failed Back Surgery Syndrome Patients: Implications for Spinal Cord Stimulation.

Authors:  S Harrison Farber; Jing L Han; Frank W Petraglia Iii; Robert Gramer; Siyun Yang; Promila Pagadala; Beth Parente; Jichun Xie; Jeffrey R Petrella; Shivanand P Lad
Journal:  Pain Physician       Date:  2017-09       Impact factor: 4.965

3.  Spinal cord stimulation for neuropathic pain: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-03-01

4.  The prevention effect of poly (L-glutamic acid)/chitosan on spinal epidural fibrosis and peridural adhesion in the post-laminectomy rabbit model.

Authors:  Chunbo Li; Hong Wang; Haifei Liu; Jingbo Yin; Lei Cui; Zenggan Chen
Journal:  Eur Spine J       Date:  2014-07-08       Impact factor: 3.134

Review 5.  Spinal cord stimulation with implanted epidural paddle lead relieves chronic axial low back pain.

Authors:  David A Stidd; Sergio Rivero; Martin E Weinand
Journal:  J Pain Res       Date:  2014-08-12       Impact factor: 3.133

Review 6.  Spinal cord stimulation: Current applications for treatment of chronic pain.

Authors:  Prasad Vannemreddy; Konstantin V Slavin
Journal:  Anesth Essays Res       Date:  2011 Jan-Jun

Review 7.  Spinal Cord Stimulation in Failed Back Surgery Syndrome: Review of Clinical Use, Quality of Life and Cost-Effectiveness.

Authors:  Przemyslaw M Waszak; Marta Modrić; Agnieszka Paturej; Stanislav M Malyshev; Agnieszka Przygocka; Hanna Garnier; Tomasz Szmuda
Journal:  Asian Spine J       Date:  2016-12-08

Review 8.  Neuropathic Pain after Spinal Surgery.

Authors:  Jae Hwan Cho; Jae Hyup Lee; Kwang-Sup Song; Jae-Young Hong
Journal:  Asian Spine J       Date:  2017-08-07

9.  A multi-center, randomized controlled clinical trial, cost-effectiveness and qualitative research of electroacupuncture with usual care for patients with non-acute pain after back surgery: study protocol for a randomized controlled trial.

Authors:  Byung-Cheul Shin; Jae-Heung Cho; In-Hyuk Ha; In Heo; Jun-Hwan Lee; Koh-Woon Kim; Me-Riong Kim; So-Young Jung; Ojin Kwon; Nam-Kwen Kim; Haeng-Mi Son; Dong-Wuk Son; Kyung-Min Shin
Journal:  Trials       Date:  2018-01-24       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.